Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
Public ClinicalTrials.gov record NCT02307279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes
Study identification
- NCT ID
- NCT02307279
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Lead sponsor
- Gelesis, Inc.
- Industry
- Enrollment
- 436 participants
Conditions and interventions
Conditions
Interventions
- Gelesis100 Device
- placebo Device
Device
Eligibility (public fields only)
- Age range
- 22 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2014
- Primary completion
- May 31, 2017
- Completion
- May 31, 2017
- Last update posted
- Aug 29, 2022
2014 – 2017
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Anaheim | California | 92801 | — |
| Investigative Site | San Diego | California | 92103 | — |
| Investigative Site | Tustin | California | 92780 | — |
| Investigative Site | Walnut Creek | California | 94598 | — |
| Investigative Site | West Hills | California | 91307 | — |
| Investigative Site | Aurora | Colorado | 80045 | — |
| Investigative Site | Jacksonville | Florida | 32205 | — |
| Investigative Site | Miami | Florida | 33143 | — |
| Investigative Site | Boise | Idaho | 83642 | — |
| Investigative Site | Chicago | Illinois | 60208 | — |
| Investigative Site | Baton Rouge | Louisiana | 70808 | — |
| Investigative Site | Boston | Massachusetts | 02115 | — |
| Investigative Site | Las Vegas | Nevada | 89401 | — |
| Investigative Site | New York | New York | 10065 | — |
| Investigative Site | Raleigh | North Carolina | 27612 | — |
| Investigative Site | Cincinnati | Ohio | 45219 | — |
| Investigative Site | Columbus | Ohio | 43212 | — |
| Investigative Site | Columbus | Ohio | 43213 | — |
| Investigative Site | Danville | Pennsylvania | 17822 | — |
| Investigative Site | Nashville | Tennessee | 37203 | — |
| Investigative Site | Dallas | Texas | 75246 | — |
| Investigative Site | Round Rock | Texas | 78681 | — |
| Investigative Site | West Jordan | Utah | 84088 | — |
| Investigative Site | Norfolk | Virginia | 23606 | — |
| Investigative Site | Richmond | Virginia | 23294 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02307279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 29, 2022 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02307279 live on ClinicalTrials.gov.